BRAUN
25.8.2021 11:02:05 CEST | Business Wire | Press release
Braun today officially announced the judging panel for the 21st BraunPrize; an international design competition that aims to promote the work of young designers, creatives and inventors, every three years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210825005057/en/
Established in 1968, the historic BraunPrize was Germany’s first international competition and its commitment to nurturing young talent has been highly regarded by the design world and the design-aware public ever since.
This year, young, up-and-coming designers and inventors have been tasked to help ‘Shape Tomorrow’ – a call to action to explore good design that will address and solve the challenges of today and tomorrow.
The judging panel for this prestigious prize includes internationally renowned experts who will honor visionary ideas and clever solutions that will help promote behavioural change and make an impact on today’s society and the future of the planet with $100,000 USD. The winning submissions will be recognised and awarded by the jurors at a virtual awards ceremony in November.
The 21st edition of the BraunPrize is set to exceed the last competition held in 2018, which received 3,087 entrants from 107 counties.
The judges for the 2021 BraunPrize are:
- Virgil Abloh, Chief Creative Director and founder of Off-White ™ and Men’s Artistic Director at Louis Vuitton (USA)
- Cecilie Manz, Designer and founder of Cecilie Manz Studio (Denmark)
- Johanna Schoemaker, Former BraunPrize Winner and owner of sustainable jewellery brand Quite Quiet (Germany)
- Li Ningning, Director of Industrial Design across the Xiaomi Ecosystem (China)
- Sukwoo Lee, Founder of SWNA (South Korea)
- Gary Hustwit, Filmmaker, and visual artist based in New York (USA)
- Stefan Schamberg, Vice President R&D, Grooming Braun and Devices (Germany)
- Prof. Oliver Grabes, Head of Design at Braun and Chairman of the BraunPrize (Germany)
Prof. Oliver Grabes said: “It was important that this year’s competition reflects the international and digital-first nature of the world we live in today. We’re excited to have assembled a diverse group of some of the most talented creative leaders from across the globe. It is a privilege to have their expertise to judge and award the wonderful talent that will emerge from the competition.”
Stefan Schamberg said; “When I began my career as a design engineer I was fortunate enough to take my early steps into the industry with Braun, a brand that always stands for good design, functionality and sustainable long-lastingness. The BraunPrize provides the next generation with a similar opportunity to showcase their creativity and the scope of their imagination to produce concepts that could change the world. It will be exciting to see what this young talent will produce.”
Virgil Abloh said; “As with any industry, it’s important that we nurture young up and coming talent that will continually push the boundaries of what is possible creatively. It’s an honour to be a part of a judging panel as we play our own part in helping the next generation of creatives and innovators.”
Cecilie Manz , said; “For me, encouragement of the next generation of designers is crucial.
Gary Hustwit said; “I’ve been a fan of Braun for many years, and it’s a privilege to be part of this year’s jury panel. I had the opportunity to do a deep dive into the company’s design history during my research for the film I made about Dieter Rams. The BraunPrize has an important lineage and continues to be a fantastic platform to showcase and nurture young creatives in the design industry and beyond. I’m excited to be part of this initiative and I’m really looking forward to seeing some groundbreaking new ideas.”
Li Ningning , said; “Good design is far more than designing products that are aesthetically pleasing - good design has the power to improve and change the world by thinking from the original point of the projects. The challenge Shape Tomorrow is a fantastic opportunity for young designers to address and provide solutions to several global issues we are facing”.
Sukwoo Lee , said; “It is an honour to be part of the jury for such a meaningful and important award. Whilst studying for my university degree, I was inspired by many of the BraunPrize winning submissions and I have closely followed the work of Braun and Dieter Rams throughout my career. I’m excited to see what this year’s competition will bring.”
Johanna Schoemaker said; “I was fortunate enough to have been part of the BraunPrize experience and know first-hand the impact that winning can have on a young designer’s career. I’m very excited to be joining as a judge this year, and to see what great design concepts we receive that could help to improve and change the world we live in for the better.”
The 2021 BraunPrize International Design Competition is open globally and is free to enter. Submissions are welcome from young designers and inventors with less than 5 years work experience and students of any profession.
For my information on the 2021 BraunPrize Jury Panel and the competition please visit www.braunprize.org
-----ENDS-----
Notes to editors:
Photo credits:
- Virgil Abloh - Richard Anderson
- Cecilie Manz - Casper Sejersen
- Johanna Schoemaker - Lina Zangers
- Sukwoo Lee - designpress
- Gary Hustwit by Ebru Yildiz
About the Braun Prize:
- The Braun Prize was established in 1968
- The Braun Prize 2021 marks the 21st edition of the international design competition
- In 2018, the Braun Prize received 3,087 entries from 107 countries
- The Braun Prize 2021 is organized by Braun, a Procter & Gamble brand, and managed by the Braun Design Team in Kronberg, Germany
About Braun:
- Braun, a subsidiary of Procter & Gamble founded in Germany in 1921, develops and manufactures a wide variety of small domestic appliances that marry technical innovation, reliable quality, and distinctive design. These range from electric shavers and beauty products to hair care appliances. Braun products enjoy worldwide distribution. Please visit www.braun.com for the latest news and in-depth information about the Braun brand.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210825005057/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
